CureVac inks lung cancer vax partnership with Boehringer; DynPort sues Lonza over vaccine manufacturing subcontract;

> CureVac has banked a $45 million upfront payment from Boehringer Ingelheim to partner its therapeutic lung cancer vaccine with the German pharma's Gilotrif. More

> DynPort Vaccine, which develops vaccines for the military, has sued Lonza Biologics, alleging the company backed out of a subcontract to manufacture a vaccine and made off with $18.9 million. Report (sub. req.)

> A law firm representing the bulk of patients who developed narcolepsy after being vaccinated with GlaxoSmithKline's ($GSK) swine flu shot Pandemrix does not expect to go to trial before March of 2016. Report

> The Japanese Global Health Fund has awarded a combined $33.5 million to companies and orgnizations including Takeda, Eisai and the PATH Malaria Vaccine Initiative to fund vaccine and drug development for neglected diseases. Release

> GlaxoSmithKline's vaccines unit has agreed to pay a civil penalty of $172,900 to resolve a Clean Air Act violation from a facility in Hamilton, MT. Report

> With Texas Gov. Rick Perry in attendance, Texas A&M University will dedicate a pandemic influenza vaccine facility Thursday. More

And Finally... Vaccination rates in elite Los Angeles schools are now worse than in Southern Sudan. More

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.